- Raw materials
- Antibacterials
- Oleandomycin
Oleandomycin API Manufacturers & Suppliers
0 verified results
All Oleandomycin data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Oleandomycin | CAS No: 3922-90-5 | GMP-certified suppliers
A medication that provides antibacterial effects for systemic infections, primarily used in veterinary medicine, with added cytochrome P450 enzyme inhibition properties.
Therapeutic categories
Product Snapshot
- Oleandomycin is administered as an oral macrolide antibiotic
- It is primarily used for antibacterial applications in veterinary medicine
- The compound is approved for veterinary use, with no current human FDA or EMA approval
Clinical Overview
From a chemical and pharmacological perspective, oleandomycin exhibits antibacterial activity by interfering with bacterial protein synthesis, a common mechanism within the macrolide class. While specific pharmacodynamics and detailed mechanisms of action for oleandomycin are not extensively documented, macrolides generally exert their effect by binding to the 50S ribosomal subunit in susceptible bacteria, thereby inhibiting peptide chain elongation.
Oleandomycin is identified as an inhibitor of cytochrome P450 enzymes, notably CYP3A and CYP3A4 isoforms. This enzymatic inhibition may have implications for drug-drug interactions when administered concomitantly with substrates metabolized by these pathways.
The Absorption, Distribution, Metabolism, and Excretion (ADME) profile of oleandomycin is not comprehensively characterized in published literature. Given its veterinary approval and limited human clinical application, detailed human pharmacokinetic parameters are sparse. However, macrolides typically exhibit good tissue penetration and hepatic metabolism involving cytochrome P450 enzymes.
Safety and toxicity data are limited, but as with other macrolides, potential adverse effects could include gastrointestinal disturbances and hypersensitivity reactions. The lower efficacy of oleandomycin compared to erythromycin has influenced its relatively limited human use and preference for veterinary applications.
Oleandomycin is not widely marketed under major brand names in human medicine but may be incorporated into formulations intended for animal health. Manufacturers and sourcing professionals should ensure the API complies with veterinary pharmaceutical standards and originates from reliable microbial fermentation processes involving authenticated Streptomyces antibioticus strains. Due diligence in quality control, including microbial purity and consistent potency, is essential when procuring oleandomycin for pharmaceutical development or veterinary formulations.
Identification & chemistry
| Generic name | Oleandomycin |
|---|---|
| Molecule type | Small molecule |
| CAS | 3922-90-5 |
| UNII | P8ZQ646136 |
| DrugBank ID | DB11442 |
Formulation & handling
- Oleandomycin is a small molecule aminoglycoside antibiotic primarily formulated for oral administration.
- It exhibits moderate lipophilicity (LogP 2.98) and low water solubility, which may impact dissolution and bioavailability.
- Handling should consider its peptide-like structure with sensitivity to hydrolysis, requiring controlled storage conditions to maintain stability.
Regulatory status
Oleandomycin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
